Central Pharmaceutical Joint Stock Company No3

HNX:DP3 Stock Report

Market Cap: ₫1.4t

Central Pharmaceutical No3 Past Earnings Performance

Past criteria checks 6/6

Central Pharmaceutical No3 has been growing earnings at an average annual rate of 8.4%, while the Pharmaceuticals industry saw earnings growing at 12.1% annually. Revenues have been growing at an average rate of 1% per year. Central Pharmaceutical No3's return on equity is 25.1%, and it has net margins of 31.3%.

Key information

8.4%

Earnings growth rate

7.0%

EPS growth rate

Pharmaceuticals Industry Growth13.0%
Revenue growth rate1.0%
Return on equity25.1%
Net Margin31.3%
Last Earnings Update31 Mar 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Central Pharmaceutical No3 makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

HNX:DP3 Revenue, expenses and earnings (VND Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 24393,686123,070133,9050
31 Dec 23409,731125,263144,6180
30 Sep 23437,247115,462169,1150
30 Jun 23454,355112,885182,6540
31 Mar 23478,070110,902203,0100
31 Dec 22485,074108,824208,7170
30 Sep 22466,732100,148208,8130
30 Jun 22439,43297,217197,1980
31 Mar 22410,10698,580164,3880
31 Dec 21381,07794,305151,4910
30 Sep 21377,540100,467145,0370
30 Jun 21384,213106,614142,3690
31 Mar 21381,982109,143139,2420
31 Dec 20395,721114,061140,3830
30 Sep 20390,30879,192170,3410
30 Jun 20414,64184,092176,9590
31 Mar 20417,25284,281161,3530
31 Dec 19411,43382,804159,9120
30 Sep 19422,77678,546171,4280
30 Jun 19433,39678,929172,0160
31 Mar 19451,12582,658185,4950
31 Dec 18471,50380,071194,9040
30 Sep 18439,46192,382156,6190
31 Dec 17328,14138,335138,5890
30 Sep 17321,38330,929138,8910
31 Dec 16237,63422,50389,1650
30 Sep 16224,75020,74883,1890
31 Dec 15212,09816,22076,0320
30 Sep 15198,8748,69569,0410
30 Jun 15191,6137,99662,0610
31 Mar 15187,9559,84359,0810
31 Dec 14184,29611,69056,1020
01 Jan 14151,8807,94345,4670

Quality Earnings: DP3 has high quality earnings.

Growing Profit Margin: DP3's current net profit margins (31.3%) are higher than last year (23.2%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: DP3's earnings have grown by 8.4% per year over the past 5 years.

Accelerating Growth: DP3's earnings growth over the past year (11%) exceeds its 5-year average (8.4% per year).

Earnings vs Industry: DP3 earnings growth over the past year (11%) exceeded the Pharmaceuticals industry -6.6%.


Return on Equity

High ROE: DP3's Return on Equity (25.1%) is considered high.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.